Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 4, 2015, Pages 413-419

  Wei, X L ^a   Yin, J ^a   Zou, G Y ^b   Zhang, Z T ^b   Walley, J ^b   Harwell, J ^a   Li, H T ^c   Sun, Q ^d   Li, R Z ^e   Wang, L X ^e   Zhang, X L ^c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c SHANDONG PROVINCIAL CHEST HOSPITAL   (China)

^d SHANDONG UNIVERSITY   (China)

^e National Center for TB Control and Prevention   (China)

Author keywords

Community management; DOT; Family members; MDR TB; Treatment interruption

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; ETHAMBUTOL; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CHINA; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DRUG SUBSTITUTION; FAMILY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIDRUG RESISTANT TUBERCULOSIS; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; SOCIAL SUPPORT; THERAPY; TREATMENT INTERRUPTION; DISEASE MANAGEMENT; MEDICATION COMPLIANCE; MIDDLE AGED; PROCEDURES; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

ADULT; ANTITUBERCULAR AGENTS; CHINA; DIRECTLY OBSERVED THERAPY; DISEASE MANAGEMENT; FAMILY; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 84925608952     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0485     Document Type: Article

References (31)

1. World Health Organization. Global tuberculosis report. WHO/HTM/TB/2013.11. Geneva, Switzerland: WHO, 2013.
2. Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl Med J 2012; 366: 2161-2170.
3. Mi F, Wang L, Li L, et al. Effect analysis of China Global Fund Multi-Drug Resistant Tuberculosis Project. J Chin Antituberculosis Assoc 2010; 11: 700-704.
4. Shean K P, Willcox P A, Siwendu S N, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis 2008; 12: 1182-1189.
5. Johnston J C, Shahidi N C, Sadatsafavi M, Fitzgerald J M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLOS ONE 2009; 4: e6914.
6. Orenstein EW, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
7. Podewils L J, Gler M T, Quelapio M I, Chen M P. Patterns of treatment interruption among patients with multidrug-resistant TB (MDR-TB) and association with interim and final treatment outcomes. PLOS ONE 2013; 8: e70064.
8. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2008.402. Geneva, Swizerland: WHO, 2008.
9. Leimane V, Riekstina V, Holtz T H, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326.
10. Brust J C, Shah N S, Scott M, et al. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberc Lung Dis 2012; 16: 998-1004.
11. Shin S, Furin J, Bayona J, Mate K, Kim J Y, Farmer P. Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc Sci Med 2004; 59: 1529-1539.
12. Toczek A, Cox H, du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2013; 17: 299-307.
13. Wei X, Zhang X, Yin J, et al. Changes in pulmonary tuberculosis prevalence: evidence from the 2010 population survey in a populous province of China. BMC Infect Dis 2014; 14: 21.
14. He G X, Zhao Y L, Jiang G L, et al. Prevalence of tuberculosis drug resistance in 10 provinces of China. BMC Infect Dis 2008; 8: 166.
15. Wang Y, Wang L X, Xu S F, Chen M T. [Work plan of prevention and control for multidrug resistant tuberculosis]. Beijing, China: Military Medical Science Publishing House, 2012. [Chinese]
16. Calver A D, Falmer A A, Murray M, et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 2010; 16: 264-271.
17. Chiang C Y, Van Deun A, Enarson D A. A poor drug-resistant tuberculosis programme is worse than no programme: time for a change [Perspective]. Int J Tuberc Lung Dis 2013; 17: 714-718.
18. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 2006; (2): CD003343.
19. Hu D, Liu X, Cheng J, et al. Direct observation and adherence to tuberculosis treatment in Chongqing, China: a descriptive study. Health Policy Plan 2008; 23: 43-55.
20. Sun Q, Meng Q Y, Yip W, Yin X, Li H. DOT in rural China: experience from a case study in Shandong Province, China. Int J Tuberc Lung Dis 2008; 12: 625-630.
21. Wei X, Liang X, Liu F, Walley J, Dong B. Decentralising tuberculosis services from county tuberculosis dispensaries to township hospitals in China: an intervention study. Int J Tuberc Lung Dis 2008; 12: 538-547.
22. Mesfin M M, Newell J N, Walley J D, et al. Quality of tuberculosis care and its association with patient adherence to treatment in eight Ethiopian districts. Health Policy Plan 2009; 24: 457-466.
23. Walley J, Khan A, Newell J, Khan M. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet 2001; 357: 664-669.
24. Newell J N, Baral S C, Pande S B, Bam D S, Malla P. Familymember DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial. Lancet 2006; 367: 903-909.
25. Zwarenstein M, Schoeman J, Vundule C, Lombard C, Tatley M. A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis. Int J Tuberc Lung Dis 2000; 4: 550-554.
26. Khan A, Walley J, Witter S, Imran A, Safdar N. Cost and costeffectiveness of different DOT strategies for the treatment of tuberculosis in Pakistan. Health Policy Plan 2002; 17: 178-186.
27. He G X, Xie G Y, Wang L X, et al. Follow-up of patients with multidrug resistant tuberculosis four years after standardized first-line drug treatment. PLOS ONE 2010; 5: 1-6.
28. Wei X, Walley J, Liang X, Liu F, Zhang X, Li R. Adapting a generic tuberculosis control operational guideline and scaling it up in China: a qualitative case study. BMC Public Health 2008; 8: 260.
29. Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmaco Economics 2012; 30: 63-80.
30. Long Q, Smith H, Zhang T, Tang S, Garner P. Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review. BMC Public Health 2011; 11: 393.
31. Wei X, Zou G, Yin J, Walley J, Sun Q. Comparing patient care seeking pathways in three models of hospital and TB programme collaboration in China. BMC Infect Dis 2013; 13: 93.